Effect of amlodipine and telmisartan on bone metabolism markers in newly diagnosed hypertensive patients.

Hypertension may adversely affect bone health, but the skeletal effects of commonly prescribed antihypertensive drugs remain inadequately u nderstood. In this 24-week prospective study, 96 newly diagnosed Stage I hypertensive patients received either Amlodipine (5-10 mg) or Telmisartan (40-80 mg), with serial assessment of bone metabolism markers. Both drugs achieved comparable blood pressure control throughout the study period. Telmisartan significantly reduced PTH and IL-6 levels while enhancing BS-ALP and transiently increasing osteocalcin, whereas Amlodipine demonstrated only a temporary rise in BS-ALP. Thus, data shows the telmisartan may provide additional benefits on bone remodeling and skeletal health in hypertensive patients at risk of fragility.